How To Optimize Early-Phase Drug Development

A Biopharma Dive survey revealed that biopharmaceutical executives face significant challenges during preclinical and Phase I clinical development, with 45% citing tight deadlines and 50% pointing to multiple contract negotiations as major issues. Miscommunications in project management were another frustration for 29% of respondents.

Altasciences addresses these concerns by offering an integrated approach to early-phase drug development, providing a single contract and point of contact throughout the process. Their "Tell Us Once™" system minimizes repetition, while customized roadmaps and centralized scheduling ensure flexibility and efficiency. This streamlined approach reduces timelines by up to 40%, offering sponsors smoother project transitions and better communication.